Literature DB >> 7103454

Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.

H J Field.   

Abstract

Mice inoculated in the ear pinna with herpes simplex virus were treated effectively by including 1 mg of acyclovir per ml in the drinking water. During a 5-day course of treatment the development of resistance was not readily apparent. However, when a suboptimal therapeutic dose was used and virus was repeatedly inoculated into further mice undergoing therapy, the infection became completely refractory to treatment by passage 4. Some of the viruses isolated exhibited reduced ability to induce thymidine kinase, and this appeared to account at least in part for the development of resistance. However, the viruses isolated from the tissues of such mice comprised complex mixtures of strains with widely differing in vitro susceptibilities to acyclovir. The properties of these virus yields gave an indication of the likely nature of resistance to nucleoside analogs in humans and suggested some difficulties which may be encountered when clinical specimens are analyzed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7103454      PMCID: PMC182005          DOI: 10.1128/AAC.21.5.744

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity.

Authors:  A A Nash; H J Field; R Quartey-Papafio
Journal:  J Gen Virol       Date:  1980-06       Impact factor: 3.891

2.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

3.  The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice.

Authors:  H J Field; P Wildy
Journal:  J Hyg (Lond)       Date:  1978-10

4.  A virus-specific thymidine kinase in BHK-21 cells infected with herpes simplex virus.

Authors:  H G Klemperer; G R Haynes; W I Shedden; D H Watson
Journal:  Virology       Date:  1967-01       Impact factor: 3.616

5.  Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease.

Authors:  T J Hill; H J Field; W A Blyth
Journal:  J Gen Virol       Date:  1975-09       Impact factor: 3.891

6.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

7.  In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).

Authors:  K O Smith; W L Kennell; R H Poirier; F T Lynd
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells.

Authors:  G Darby; B A Larder; K F Bastow; H J Field
Journal:  J Gen Virol       Date:  1980-06       Impact factor: 3.891

9.  Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.

Authors:  H J Field; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

10.  Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice.

Authors:  H J Field; S E Bell; G B Elion; A A Nash; P Wildy
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

View more
  21 in total

Review 1.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

2.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.

Authors:  M Lipsitch; T H Bacon; J J Leary; R Antia; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  L R Stanberry; S Kit; M G Myers
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

5.  Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene.

Authors:  H J Field; D M Coen
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

6.  Comparative methods for detection of thymidine kinase-deficient herpes simplex virus type 1 strains.

Authors:  J Harmenberg; V A Sundqvist; H Gadler; B Levén; G Brännström; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

7.  In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.

Authors:  E L Hill; G A Hunter; M N Ellis
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 8.  Chemotherapy for herpes simplex virus infections.

Authors:  K S Erlich; J Mills
Journal:  West J Med       Date:  1985-11

Review 9.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

10.  Long term oral acyclovir in disseminated mucocutaneous herpes simplex: a case report.

Authors:  A Mindel
Journal:  Br J Vener Dis       Date:  1984-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.